ELOVL4 Polyclonal Antibody

Rabbit Anti-ELOVL4 Polyclonal Antibody

Product Specifications

Background

ELOVL4 encodes a membrane-bound protein which is a member of the ELO family, proteins which participate in the biosynthesis of fatty acids. Consistent with the expression of the encoded protein in photoreceptor cells of the retina, mutations and small deletions in ELOVL4 are associated with Stargardt-like macular dystrophy (STGD3) and autosomal dominant Stargardt-like macular dystrophy (ADMD), also referred to as autosomal dominant atrophic macular degeneration.

CAS Number

9007-83-4

Product Name Alternative

ELOVL4; Elongation of very long chain fatty acids protein 4; 3-keto acyl-CoA synthase ELOVL4; ELOVL fatty acid elongase 4; ELOVL FA elongase 4

Gene ID

6785

Accession Number

Q9GZR5

Reactivity

Human, Mouse

Immunogen

Synthesized peptide derived from the Internal region of human ELOVL4 at AA range: 10-90

Clonality

Polyclonal

Tag

Elongation of very long chain fatty acids protein 4

Applications

WB, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

37kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

ELOVL4 Polyclonal Antibody detects endogenous levels of ELOVL4 protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; ELISA 1:40000; Not yet tested in other applications.